Cases : Healthcare Fraud

Acting as lead counsel and head of the discovery committee to a putative class of direct purchasers of brand name and generic equivalents of extended-release venlafaxine hydrochloride capsules against drug manufacturers. Among the claims, defendants are alleged to have delayed market entry of generic versions and entered reverse payment settlements.

In re Prograf Antitrust Litigation, 11-md-02242 (D. Mass. 2015).  Representation of direct purchaser class.  $98 million settlement.

Schuette, Attorney General of the State of Michigan ex rel. The State of Michigan v. McKesson Corporation, No. 11-629-CZ (Ingham Cty. Cir. Ct. 2012).  Representation of the State of Michigan.  McKesson paid approximately $155 million to settle claims by Michigan and a number of other states.

In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456; City of New York v. Abbott Laboratories, No. 01-cv-12257 (D. Mass. 2010).  KM represented the State of Iowa, the City of New York, and forty-two New York State counties in a lawsuit against forty defendant drug manufacturers asserting that they manipulated their average wholesale price data to inflate prices charged to government drug benefits payers.  Recovery of over $225 million for the plaintiffs.

City of New York v. The Purdue Pharma Company, No. 04-cv-03499 (S.D.N.Y.).  Representation of the City of New York.  Over $1 million recovery for the City Medicaid Program.

City of New York v. GlaxoSmithKline Plc, No. 04-cv-02134 (D. Pa. 2004).  Representation of the City of New York.  Over $1 million recovery for the City Medicaid Program.